Michael Højby Rasmussen (Michael H Rasmussen, Michael Højby)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 19

Top Topics

Gestational Age

Top Venues

Clinical endocrinology

Clinical pharmacokinetics

The Journal of clinical endocrinology and metabolism

Journal of the Endocrine Society

This page only lists publications with an associated author ORCID identifier.

Publications

Jun Mori, Yasuhisa Ohata, Yasuko Fujisawa, Yukihito Sato, Sebastian Röhrich, Michael Højby Rasmussen, Rikke Beck Bang, Reiko Horikawa
Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial. Clinical endocrinology 100 (4) (2024)
Anders Juul, Philippe F Backeljauw, Michael Højby Rasmussen, Jan Frystyk, Masanobu Kawai, Rasmus Juul Kildemoes, Anders Krogh Lemminger, Agnès Linglart, Nehama Zuckerman Levin, Reiko Horikawa
Somapacitan in Children Born SGA: 52-week Efficacy, Safety, and IGF-I Response Results from the Phase 2 REAL5 Study. The Journal of clinical endocrinology and metabolism (2024)
Sarah Louise Dombernowsky, Birgitte Bentz Damholt, Michael Højby Rasmussen, Claus Sværke, Rasmus Juul Kildemoes
Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial. Clinical pharmacokinetics 63 (7) (2024)
Jun Mori, Yasuhisa Ohata, Yasuko Fujisawa, Yukihito Sato, Sebastian Röhrich, Michael Højby Rasmussen, Rikke Beck Bang, Reiko Horikawa
Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial. Clinical endocrinology 100 (4) (2024)
Sarah Louise Dombernowsky, Birgitte Bentz Damholt, Michael Højby Rasmussen, Claus Sværke, Rasmus Juul Kildemoes
Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial. Clinical pharmacokinetics (2024)
Sarah Louise Dombernowsky, Birgitte Bentz Damholt, Michael Højby Rasmussen, Claus Sværke, Rasmus Juul Kildemoes
Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial. Clinical pharmacokinetics 63 (7) (2024)
Sarah Louise Dombernowsky, Birgitte Bentz Damholt, Michael Højby Rasmussen, Claus Sværke, Rasmus Juul Kildemoes
Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial. Clinical pharmacokinetics 63 (7) (2024)
Jun Mori, Yasuhisa Ohata, Yasuko Fujisawa, Yukihito Sato, Sebastian Röhrich, Michael Højby Rasmussen, Rikke Beck Bang, Reiko Horikawa
Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial. Clinical endocrinology (2024)
Jun Mori, Yasuhisa Ohata, Yasuko Fujisawa, Yukihito Sato, Sebastian Röhrich, Michael Højby Rasmussen, Rikke Beck Bang, Reiko Horikawa
Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial. Clinical endocrinology (2024)
Jun Mori, Yasuhisa Ohata, Yasuko Fujisawa, Yukihito Sato, Sebastian Röhrich, Michael Højby Rasmussen, Rikke Beck Bang, Reiko Horikawa
Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial. Clinical endocrinology 100 (4) (2024)
Sarah Louise Dombernowsky, Birgitte Bentz Damholt, Michael Højby Rasmussen, Claus Sværke, Rasmus Juul Kildemoes
Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial. Clinical pharmacokinetics 63 (7) (2024)
Bradley S Miller, Joanne C Blair, Michael Højby Rasmussen, Aristides Maniatis, Jun Mori, Volker Böttcher, Ho-Seong Kim, Rikke Beck Bang, Michel Polak, Reiko Horikawa
Effective GH Replacement with Somapacitan in Children with GHD: REAL4 2-year Results and after Switch from Daily GH. The Journal of clinical endocrinology and metabolism (2023)
Rasmus Juul Kildemoes, Philippe F Backeljauw, Michael Højby Rasmussen, Joanne C Blair, Bradley S Miller, Jun Mori, Yassine K Lyauk
Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency. Journal of the Endocrine Society 7 (11) (2023)
Yutaka Takahashi, Beverly M K Biller, Hidenori Fukuoka, Ken K Y Ho, Michael Højby Rasmussen, Navid Nedjatian, Claus Sværke, Kevin C J Yuen, Gudmundur Johannsson
Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency. Pituitary (2022)
Bradley S Miller, Joanne C Blair, Michael Højby Rasmussen, Aristides Maniatis, Rasmus Juul Kildemoes, Jun Mori, Michel Polak, Rikke Beck Bang, Volker Böttcher, Stefano Stagi, Reiko Horikawa
Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial. The Journal of clinical endocrinology and metabolism 107 (12) (2022)
Lars Sävendahl, Tadej Battelino, Meryl Brod, Michael Højby Rasmussen, Rasmus Juul Kildemoes, Paul Saenger
Letter to the Editor from L. Sävendahl et al.: "Weekly Lonapegsomatropin in Treatment-Naïve Children with Growth Hormone Deficiency: The Phase 3 heiGHt Trial". The Journal of clinical endocrinology and metabolism (2021)
Birgitte Bentz Damholt, Sarah Louise Dombernowsky, Mette Dahl Bendtsen, Charlotte Bisgaard, Michael Højby Rasmussen
Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials. Clinical pharmacokinetics 60 (8) (2021)
Fumio Otsuka, Yutaka Takahashi, Shigeyuki Tahara, Yoshihisa Ogawa, Michael Højby Rasmussen, Koji Takano
Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once-weekly somapacitan or daily growth hormone. Clinical endocrinology 93 (5) (2020)
Tadej Battelino, Michael Højby Rasmussen, Jean De Schepper, Nehama Zuckerman-Levin, Zoran Gucev, Lars Sävendahl, null null
Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial. Clinical endocrinology 87 (4) (2017)